Biocon Pharma Ltd’s arm has received Health Canada approval for micafungin for injection, aimed at serious fungal infections in both adults and children. The treatment will be used for conditions such as candidemia and esophageal candidiasis, and the approval extends to prophylaxis for stem cell transplant patients. The decision adds a key new offering to Biocon’s portfolio.
Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a compliance notice from Health Canada for its cancer biosimilar Bevqolva, a bevacizumab-based treatment used across multiple cancers. The development signals Health Canada’s confirmation of safety and efficacy, paving the way for broader access to potential cost-effective options for patients in Canada.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Dr Reddy’s Laboratories has received market authorization from Health Canada for its generic semaglutide injection, becoming the first company approved for the diabetes therapy in Canada. The Bengaluru-based pharma is now preparing a launch to expand access for patients who rely on the treatment, potentially easing pressure on medication availability and costs.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
